In search of protective correlation factors for dengue: Comparison of the effects caused by Dengue virus infection with the effects of the QDenga vaccine in different age groups

Phase 1

• Conditions: Dengue; C01.920.500

• Registration Number: RBR-7k3nv44
• Lead Sponsor: niversidade Federal de Minas Gerais

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-08-13
• Last Update Posted: 19 August 2024
• Study Completion: 2025-03-01

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Vaccination cohort: Participants between 18 to 90 years of age who agree to participate in the study. Absence of an acute clinical condition at the time of vaccination. Infected cohort: Participants under 18 yeas old. Participants with more than 5 days of symptoms. Participants who do not agree to sign the informed consent form. Participants who are not available to carry out the planned study visits

Exclusion Criteria

Vaccination cohort: Participants under 18 years old. Participants who are not available to carry out the planned visits of the study. Participants who do not agree to sign the informed consent form. Positive beta Human Chorionic Gonadotropin on the day of vaccination, in the case of women of reproductive potential. Participants who are pregnant or planning to become pregnant within the next 3 months after the last vaccine dose. Participants breastfeeding. Participant with a known or suspected immune system defect that may influence the immunological response to the vaccine, such as participants with congenital or acquired immunodeficiency, including human immunodeficientcy virus infection, post-organ transplant status or immunosuppressive therapy within 4 weeks prior to Visit 1. Therapy Immunosuppressive is defined as chronic administration of prednisone (more than 14 days) or equivalent more or equal than 2 miligramas por kilo por dia in the 4 weeks prior to study entry, radiotherapy or immunosuppressive cytotoxic drugs or monoclonal antibodies in the 3 previous years, topical and inhaled steroids are permitted. Infected cohort: Participants with more than 5 days of symptoms. Participants who do not agree to sign the Informed consent form. Participants who are not available to carry out the planned study visits

Study & Design

• Study Type: Intervention
• Study Design: Not specified